Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:ENGN NASDAQ:KLRS NASDAQ:TAOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.64-11.5%$0.94$0.63▼$10.95$88.89M1.711.46 million shs2.26 million shsENGNenGene$1.64-4.7%$4.91$1.40▼$12.25$109.86M-0.32.81 million shs952,721 shsKLRSKalaris Therapeutics$4.44-4.7%$5.50$2.14▼$11.88$105.64M0.1582,088 shs140,751 shsTAOXSynaptogenix$3.81-6.2%$5.06$2.38▼$11.98$28.47M1.41137,561 shs176,961 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-11.45%-25.30%-33.08%-53.93%-93.47%ENGNenGene-4.65%-11.35%-81.47%-81.11%-57.18%KLRSKalaris Therapeutics-4.72%-15.75%-12.25%-54.79%+43.69%TAOXSynaptogenix-6.16%-9.29%-40.84%-4.03%+380,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.64-11.5%$0.94$0.63▼$10.95$88.89M1.711.46 million shs2.26 million shsENGNenGene$1.64-4.7%$4.91$1.40▼$12.25$109.86M-0.32.81 million shs952,721 shsKLRSKalaris Therapeutics$4.44-4.7%$5.50$2.14▼$11.88$105.64M0.1582,088 shs140,751 shsTAOXSynaptogenix$3.81-6.2%$5.06$2.38▼$11.98$28.47M1.41137,561 shs176,961 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-11.45%-25.30%-33.08%-53.93%-93.47%ENGNenGene-4.65%-11.35%-81.47%-81.11%-57.18%KLRSKalaris Therapeutics-4.72%-15.75%-12.25%-54.79%+43.69%TAOXSynaptogenix-6.16%-9.29%-40.84%-4.03%+380,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AENGNenGene 2.21Hold$12.68673.28% UpsideKLRSKalaris Therapeutics 2.75Moderate Buy$15.60251.35% UpsideTAOXSynaptogenix 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TAOX, KLRS, ENGN, and AIFC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.005/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform5/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$25.00 ➝ $2.005/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$2.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M3.58N/AN/A$9.07 per share0.07ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/ATAOXSynaptogenix$687.84K41.39N/AN/A$2.83 per share1.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/AENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%6/11/2026 (Estimated)KLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ATAOXSynaptogenix-$28.74M-$13.28N/AN/AN/AN/A-163.40%-133.47%N/ALatest TAOX, KLRS, ENGN, and AIFC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q2 2026ENGNenGene-$0.48N/AN/AN/AN/AN/A5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/13/2026Q1 2026TAOXSynaptogenixN/A$0.43N/A$0.43N/A$5.96 million5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/31/2026Q4 2025TAOXSynaptogenixN/A$1.03N/A$1.03N/A($2.46) million3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A3/9/2026Q1 2026ENGNenGene-$0.55-$0.44+$0.11-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82ENGNenGene0.0911.7511.75KLRSKalaris TherapeuticsN/A12.1912.19TAOXSynaptogenixN/A27.3927.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%ENGNenGene64.16%KLRSKalaris Therapeutics66.05%TAOXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%ENGNenGene10.50%KLRSKalaris Therapeutics68.10%TAOXSynaptogenix2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/AENGNenGene3166.99 million59.95 millionN/AKLRSKalaris Therapeutics11023.79 million7.59 millionN/ATAOXSynaptogenix47.47 million7.27 millionN/ATAOX, KLRS, ENGN, and AIFC HeadlinesRecent News About These CompaniesTAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI InnovationNovember 18, 2025 | prnewswire.comTradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and SynopsysNovember 11, 2025 | prnewswire.comTAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet FundsNovember 4, 2025 | prnewswire.comTAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI CryptocurrencyOctober 20, 2025 | prnewswire.comTAO Synergies Announces $11 Million Private PlacementOctober 13, 2025 | prnewswire.comTAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)September 22, 2025 | prnewswire.comTAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI EventSeptember 8, 2025 | prnewswire.comTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN AustinJune 26, 2025 | kxan.comKSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLAJune 26, 2025 | ktla.comKSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comLSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comMSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTAOX, KLRS, ENGN, and AIFC Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.64 -0.08 (-11.45%) As of 06/5/2026 04:00 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.enGene NASDAQ:ENGN$1.64 -0.08 (-4.65%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.62 -0.02 (-1.22%) As of 06/5/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Kalaris Therapeutics NASDAQ:KLRS$4.44 -0.22 (-4.72%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.33 -0.11 (-2.57%) As of 06/5/2026 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Synaptogenix NASDAQ:TAOX$3.81 -0.25 (-6.16%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.82 +0.02 (+0.39%) As of 06/5/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
